Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or Tennessee for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to Tennessee only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. Tennessee (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Gang Tian (NPI 1528066495)

Field	Value
Entity Type	Individual
Organization	Gang Tian
Address	7945 Wolf River Boulevard
City	Germantown
State	TN
ZIP	38138
Taxonomy	Hematology & Oncology Physician
NPI Enumerated	July 13, 2005

Payer Source	Total Paid
Medicare	$3.8M
Medicaid	$0

Key Findings

This provider’s billing is effectively single‑payer: total Medicare revenue is $3.8M while Medicaid revenue is none, indicating no Medicaid billing on file and a practice that relies entirely on Medicare for the public-payer portion of its book of business. Analysts should treat Medicare trends as representative of the provider’s public-payer activity since there is no Medicaid footprint to compare.

Revenue is highly concentrated in a few high-cost oncology infusions: the precomputed top three Medicare codes account for 61.7% of the provider’s Medicare revenue, driven by J9271 ($1.4M, 38.5%), J9299 ($488.1K, 13.3%), and J9144 ($362.5K, 9.9%). This mix — checkpoint inhibitor and monoclonal antibody codes — points to an infusion-first hematology/oncology practice focused on immunotherapy and targeted antibody treatments.

J9271 (pembrolizumab) is a national high-volume driver for this clinician: it generates $1.4M (38.5% of Medicare revenue) and is described as "notably above typical national volume" with rank #90 of 1841 (95th percentile). That standing suggests the provider is a major national participant in administering pembrolizumab relative to peers and likely maintains strong referral or internal infusion throughput for checkpoint inhibitor therapy.

The second- and third-largest revenue generators, J9299 (nivolumab, $488.1K, 13.3%) and J9144 (daratumumab, $362.5K, 9.9%), are characterized as "typical, unremarkable volume" at their national ranks, indicating these agents are meaningful contributors to revenue but that the provider’s volumes for these drugs are within expected peer ranges rather than outlier-level. Together with J9271 they form the concentrated oncology treatment backbone of the practice.

The provider appears to offer less-common or newer agents as well: J9358 (fam-trastuzumab deruxtecan-nxki) produced $174K (4.7%) and is billed by very few providers nationally (rank #3 of 6), even though it is labeled "typical, unremarkable volume" in percentile terms. That small national denominator combined with nontrivial revenue implies the practice has access to, and is administering, less-widely distributed therapies, which may differentiate it regionally or for specific tumor types.

Chemotherapy administration and infusion-support activity are also notable outliers: 96413 ($58.7K) and 96367 ($15.8K) are both labeled "notably above typical national volume" (96413 rank #377 of 7514, 95th percentile; 96367 rank #148 of 4032, 96th percentile). These signals reinforce that the practice has substantial in-office infusion throughput beyond high-cost immunotherapies, consistent with a full-spectrum outpatient oncology infusion operation.

The practice’s mix includes supportive care and programmatic payments that point to comprehensive oncology services: J0897 (denosumab, $192.2K, 5.2%), J2506 (pegfilgrastim, $33.5K, 0.9%), and M0010 (EOM monthly enhanced services, $15.3K, 0.4% with rank #58 of 544, 90th percentile) show billing for bone‑health agents, growth‑factor support, and participation in enhanced oncology model payments. These codes indicate bundled supportive care and an administrative participation in oncology care models, which can impact downstream revenue and patient management workflows.

This clinician is an established provider with a long enrollment history: the NPI was enumerated on 2005-07-13 (~21 years ago), suggesting an experienced practice likely to have stable referral sources and operational infrastructure to support the high infusion volumes observed in Medicare claims. For payer strategy and network negotiations, treat this entity as a seasoned, infusion-centric hematology/oncology practice with concentrated revenue in immunotherapy and related infusion services.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

103 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J9271	Injection, pembrolizumab, 1 mg	32,800	$40	$1.4M
J9299	Injection, nivolumab, 1 mg	21,220	$20	$488.1K
J9144	Injection, daratumumab, 10 mg and hyaluronidase‑fihj	9,540	$40	$362.5K
J0897	Injection, denosumab, 1 mg	10,680	$20	$192.2K
J9358	Injection, fam-trastuzumab deruxtecan-nxki, 1 mg	8,700	$20	$174K
J9047	Injection, carfilzomib, 1 mg	4,110	$40	$148K
J1930	Injection, lanreotide, 1 mg	3,240	$40	$142.6K
J2796	Injection, romiplostim, 10 micrograms	1,340	$70	$99.4K
Q5107	Injection, bevacizumab-awwb, biosimilar, (mvasi), 10 mg	3,640	$20	$83.7K
J1569	Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg	2,170	$40	$78.1K

Showing 1–10 of 103

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 103 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. Tennessee Distribution

Gang Tian — 4 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — Tennessee

Full comparison — all codes billed, vs. state median

103 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J9271	6	50	17,400	$40	$776.1K
J9299	9	20	21,010	$20	$487.5K
J9144	12	20	10,080	$40	$466.3K
J1569	20	30	3,030	$40	$175.2K
J1930	2	10	2,880	$40	$162K
J9358	1	10	7,850	$20	$156.7K
J9047	1	10	3,090	$40	$117.8K
J2796	1	10	1,340	$70	$98.7K
J1437	15	20	3,700	$20	$86.3K
J0897	23	240	2,940	$20	$85K

Showing 1–10 of 103

Related Providers

Other providers that share a Tax Identification Number (TIN) with Gang Tian, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
The West Clinic P.C.	TN	Specialist	$0	$16M
David Portnoy	TN	Hematology & Oncology Physician	$6.5M	$0
Kurt Tauer	TN	Medical Oncology Physician	$3.9M	$0
Jason Chandler	TN	Medical Oncology Physician	$3.8M	$0
Syed Sameer Nasir	TN	Hematology & Oncology Physician	$3.5M	$0
Ramakrishna Battini	TN	Hematology & Oncology Physician	$3.3M	$0
Eric Wiedower	TN	Hematology & Oncology Physician	$2.9M	$0
Bradley Somer	TN	Hematology & Oncology Physician	$2.8M	$0
Robert Johnson	TN	Hematology & Oncology Physician	$2.8M	$0
Sonia Benn	MS	Hematology & Oncology Physician	$2.6M	$0

Nearby Providers

Other providers in the same ZIP code as Gang Tian, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Byram Healthcare Centers, Inc.	TN	Durable Medical Equipment & Medical Supplies	$0	$44.3M
Campbell Clinic, PC	TN	Orthopaedic Surgery Physician	$0	$28M
Poplar Avenue Clinic PLLC	TN	Gynecologic Oncology Physician	$0	$9.7M
Diagnostic Ultrasound Consultants	TN	Diagnostic Radiology Physician	$0	$8.5M
Mid-south Imaging & Therapeutics, P.A.	TN	Diagnostic Radiology Physician	$0	$8.2M
Stephen Huddleston	TN	Retina Specialist (Ophthalmology) Physician	$5.7M	$0
Stern Cardiovascular Foundation, Inc	TN	Cardiovascular Disease Physician	$0	$4.7M
G I Diagnostic And Therapeutic Center LLC	TN	Endoscopy Clinic/Center	$4.2M	$8.6K
Memphis Neurology PLLC	TN	Neurology Physician	$0	$3.9M
Raza Hashmi	TN	Rheumatology Physician	$3.9M	$0

Gang Tian — Billing Profile & Reimbursement Data

Sign up for Gang Tian — Billing Profile & Reimbursement Data policy alerts

Gang Tian — Billing Profile & Reimbursement Data

Sign up for Gang Tian — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References